Improved uptake of cannabinoid based medicine

Echo Pharmaceuticals B.V. announces that initial clinical trials have proven the efficiency of its patented Alitra™ technology to enhance bioavailability. Results show that the bioavailability of Echo’s CBD (cannabidiol) product, Arvisol® is increased by 30%. This is of massive importance because it increases the convenience for patients and reduces the costs of the medication.

 

Weesp, The Netherlands – July 2015 – In the last years, the interest grew in the therapeutic benefits of cannabinoids and especially in the medical properties for different therapeutic indications of CBD. CBD has been shown to provide anti-convulsing, anti-arthritic and neuroprotective properties while not inducing any psychoactivity effect.  

Current medications using CBD request high CBD doses per patient. Echo Pharmaceuticals has patented a drug delivery technology Alitra™, to incorporate lipophilic compounds into an effective pharmaceutical dosage form. Alitra™ significantly improves absorption and distribution of compounds with low water solubility. The efficacy of Alitra™ technology to enhance bioavailability, of different lipophilic compounds, has been clinically demonstrated and implemented in Echo’s leading products Namisol® (oral tablet containing pure THC) and Arvisol® (oral tablet containing pure CBD).

The improvement of the CBD bioavailability by 30% in Echo’s Arvisol® oral tablet is of high importance because it reduces significantly the therapeutic dose of CBD. It also has a positive impact in dropping the medication cost which will directly benefit the patients.  

 

About Alitra™

Alitra™ is Echo Pharmaceuticals’ patented drug delivery technology to incorporate lipophilic compounds into an effective pharmaceutical dosage form.  Alitra™ has been clinically proved to improve significantly the absorption of lipophilic active compounds, such as cannabinoids, leading to high predictable bioavailability and low variability between patients. Alitra™ has been successfully implemented in Echo’s leading cannabis-based products Namisol® and Arvisol®.

 

About Arvisol®

The Arvisol® tablet contains pure cannabidiol (CBD) in fixed dosages with high, predictable bioavailability, due to Echo’s innovative drug delivery technology AlitraTM. Arvisol® has a long and stable shelf life at room temperature. Arvisol® is intended to be registered for the treatment of several neurological diseases as schizophrenia and epilepsy.

 

About Namisol®

Namisol® is the world’s first oral tablet that contains pure and natural Δ9-tetrahydrocannabinol (THC or dronabinol) in fixed dosages with high, predictable bioavailability and a long, stable shelf life at room temperature.  Namisol®’s current clinical program includes, in addition to the MS indication, clinical trials for Alzheimer’s disease and chronic Pain.

 

About Echo Pharmaceuticals B.V. (“Echo”)

Echo Pharmaceuticals (‘Echo’) is a privately owned specialized pharmaceutical company, with more than 10 years of experience, in leading innovation in advanced cannabis-based medicines and products. The company is headquartered in Nijmegen, The Netherlands, with offices and GMP facilities in Weesp. Echo has developed an advanced program on cannabis-based medicines and drug delivery technologies. The company’s strong and resilient IP portfolio and proprietary knowledge on conventional and advanced technologies for extraction, purification and formulation has resulted in a range of high quality market-ready products, placing Echo in a unique market position in the medicinal cannabis field.

 

To learn more about AlitraTM, Arvisol®, Namisol® & Echo Pharmaceuticals

 

Contact information:

Echo Pharmaceuticals B.V.

www.echo-pharma.com

+31(0)294 457 353

 

Melanie Wijnands - Communication Manager

melanie.wijnands@echo-pharma.com